Donna Bearden
Family · Chattanooga, TNNPI 1245589514
Payments from drug & device makers
Across 193 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$391
- CSL Behring$330
- Incyte Corporation$288
- Covis Pharma GmbH$268
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,36599%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $1,614 |
| GSK | 53 | $1,004 |
| Regeneron Healthcare Solutions, Inc. | 10 | $391 |
| CSL Behring | 15 | $330 |
| Incyte Corporation | 7 | $288 |
| Covis Pharma GmbH | 13 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $223 |
| Pfizer | 14 | $207 |
| Sanofi | 8 | $194 |
| Pharming Healthcare, Inc. | 2 | $142 |
| Organon | 1 | $123 |
| Blueprint Medicines Corporation | 1 | $109 |
| Amgen | 4 | $79 |
| Grifols USA, LLC | 3 | $66 |
| Octapharma USA, Inc. | 3 | $55 |
| Optinose US, Inc. | 2 | $47 |
| Novo Nordisk | 2 | $43 |
| Genentech USA, Inc. | 2 | $37 |
| Kaleo, Inc. | 2 | $31 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Novartis | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,425 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $55,344 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $20,637 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $12,907 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $7,828 |
| BreynaBudesonide/Formoterol Fumarate | 33 | $7,769 |
| Epinephrine | 35 | $6,744 |
| Arnuity ElliptaFluticasone Furoate | 24 | $6,041 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,966 |
| Azelastine Hcl | 147 | $4,881 |
| Montelukast Sodium | 323 | $3,595 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,301 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 136 | $2,814 |
| Fluticasone Propionate | 156 | $2,174 |
| Famotidine | 133 | $2,004 |
| Levocetirizine Dihydrochloride | 147 | $1,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,004 | $82,023139 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,614 | $20,73542 claims |
| Hikma Pharmaceuticals USAEpinephrine | $28 | $6,74435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Chattanooga
- Jennifer SparksChattanooga$120K
- Marcie BeasleyChattanooga$91K
- Amy RainsChattanooga$55K
- Bronte NaplesChattanooga$26K
- Ernest BrandtChattanooga$21K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.